^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bapotulimab (BAY 1905254)

    i
    Other names: BAY 1905254, CGEN-15001T, CGEN-15001T-targeted monoclonal antibody, BAY1905254, BAY-1905254, CGEN15001T, CGEN 15001T
    Associations

    News

    Trials
    Company:
    Compugen
    Drug class:
    ILDR2 inhibitor
    Associations

    News

    Trials
    over1year
    KEYNOTE-920: Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (clinicaltrials.gov)
    P1, N=60, Completed, Bayer | Active, not recruiting --> Completed | N=120 --> 60
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    almost3years
    Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Bayer | Trial primary completion date: Oct 2023 --> Jun 2023
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    3years
    Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> May 2024
    Enrollment closed • Trial completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    almost4years
    Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (clinicaltrials.gov)
    P1, N=120, Recruiting, Bayer | Trial completion date: May 2024 --> Oct 2025 | Trial primary completion date: Nov 2022 --> Oct 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    over5years
    Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. (clinicaltrials.gov)
    P1, N=120, Recruiting, Bayer | N=236 --> 120 | Trial completion date: Sep 2024 --> May 2024 | Trial primary completion date: Sep 2024 --> Nov 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    6years
    A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 (clinicaltrials.gov)
    P1; Trial completion date: Jul 2023 --> Sep 2024 | Trial primary completion date: Jul 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Clinical • Tumor mutational burden • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    7years
    A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 (clinicaltrials.gov)
    P1; Trial completion date: Nov 2021 --> Jul 2023 | Trial primary completion date: Nov 2021 --> Jul 2023
    Trial completion date • Trial primary completion date • Clinical • Tumor mutational burden • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    over7years
    A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 (clinicaltrials.gov)
    P1; Not yet recruiting --> Recruiting
    Enrollment open • Clinical • Tumor mutational burden • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)
    over7years
    A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 (clinicaltrials.gov)
    P1; N=196; Not yet recruiting; Sponsor:Bayer
    New P1 trial • Clinical • Tumor mutational burden • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)